Background Follicular lymphoma (FL) is the second most common type of lymphoid cancer in Western Europe. Objective The aim of this study was to evaluate the cost utility of rituximab-bendamustine treatment compared with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) treatment as a first-line therapy for patients with advanced FL in Spain. Methods A Markov model was developed to estimate the cost effectiveness of rituximab-bendamustine compared with R-CHOP as first-line treatment for patients with advanced FL in the Spanish National Health System (NHS). Transitions between health states (progression-free, including induction and maintenance; first relapse; second relapse; and death) were allowed for the patient cohort in 4-week-long cycles. Clinical data for the extrapolation of progression-free survival curves were obtained from randomized trials. Mortality rates and utilities were obtained from the literature. Outcomes were measured as quality-adjusted life-years (QALYs). The total costs (€, 2013) included drug costs (ex-factory prices with mandatory deductions), disease management costs and adverse event-associated costs. Costs and outcomes were discounted at a 3 % annual rate. Probabilistic sensitivity analysis was performed using 10,000 Monte Carlo simulations to assess the model robustness. Results Treatment and administration costs during the induction phase were higher for rituximab-bendamustine (€17,671) than for R-CHOP (€11,850). At the end of the 25-year period, the rituximab-bendamustine first-line strategy had a total cost of €68,357 compared with €69,528 for R-CHOP. Health benefits were higher for rituximabbendamustine treatment (10.31 QALYs) than for R-CHOP treatment (9.82 QALYs). In the probabilistic analysis, rituximab-bendamustine was the dominant strategy over treatment with R-CHOP in 53.4 % of the simulations. Conclusion First-line therapy with rituximab-bendamustine in FL patients was the dominant strategy over treatment with R-CHOP; it showed cost savings and higher health benefits for the Spanish NHS.
Introduction
Follicular lymphoma (FL) is the second most common type of lymphoid cancer in Western Europe [1] , representing 22-40 % of non-Hodgkin lymphoma (NHL) according to the World Health Organization (WHO) [2] .
Despite substantial improvement in survival, FL is considered an incurable disease in most cases. The disease characteristically responds well to first-line therapy but typically manifests repeated relapses with the need for recurrent therapeutic interventions with disease-free intervals.
Patients with FL in advanced stages who have a high tumour burden usually receive a front-line chemoimmunotherapy, rituximab plus chemotherapy, during the socalled induction phase, followed by maintenance therapy with rituximab in patients who achieve at least a partial response after the induction phase, as is recommended by several clinical guidelines [3] [4] [5] [6] [7] .
Randomized trials and real-world studies have demonstrated that rituximab maintenance can prolong the time to progressive disease in patients with FL [8, 9] . Nevertheless, it has not yet been established which polychemotherapy regimen should be prescribed in addition to rituximab as an induction treatment [3] . A recent publication showed that regimens based on cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) are associated with a better risk/benefit ratio than those based on cyclophosphamide, vincristine and prednisone (CVP) or fludarabine, when combined with rituximab, as a first-line FL treatment [10] .
Bendamustine is an alkylating agent approved by the European Medicines Agency (EMA) for the treatment of three different haematological malignancies: chronic lymphocytic leukaemia, NHL and multiple myeloma [11] . According to the results of the German Lymphoma Group study [12] , a combination of rituximab plus bendamustine has higher efficacy and is safer than the rituximab plus CHOP (R-CHOP) combination during the induction phase. An extension of the indications for combined treatment with rituximab as a first-line FL treatment has been approved by the EMA.
The objective of this analysis is to assess the cost effectiveness of rituximab-bendamustine compared with R-CHOP as a first-line treatment for patients with FL in Spain.
Material and Methods

A novel Markov model was developed in Microsoft Excel
Ò 2013 to simulate the long-term evolution of a hypothetical cohort of 100 patients with FL.
A lifetime horizon equivalent to 25 years was used, which allowed the assessment of the differences in costs or outcomes between the two strategies compared: treatment with rituximab-bendamustine (rituximab 375 mg/m 2 on day 1 of each chemo cycle, plus bendamustine 90 mg/m 2 on days 1 and 2 of a 4-week cycle) and treatment with R-CHOP (rituximab 375 mg/m 2 on day 1 of each chemo cycle and 3-week cycles of cyclophosphamide 750 mg/m 2 , doxorubicin 50 mg/m 2 and vincristine 1.4 mg/m 2 on day 1, together with prednisone 100 mg/day for 5 days).
The efficiency of the first-line rituximab-bendamustine therapy was estimated using the incremental cost-effectiveness ratio (ICER) of rituximab-bendamustine therapy versus R-CHOP chemotherapy, and is expressed as cost per life-year gained (LYG) and the incremental cost-utility ratio (ICUR) in terms of cost per additional quality-adjusted life-year (QALY).
Parameters
The model comprised three main health states: progression-free (PF), disease progression and death (Fig. 1 ). Both the PF and progression states included two sub-health states.
The model cycle length was 4 weeks, which was appropriate for the rituximab-bendamustine administration cycle. An adjustment was needed to convert R-CHOP chemo cycles (every 3 weeks) to the noted model cycle length.
An average patient of the assessed cohort was defined as aged 58 years old [13] at model entry, with an average weight of 68 kg and average body surface of 1.7 m 2 , these characteristics are typical of the Spanish patient population [14] .
The development of this simulation is justified by the absence of head-to-head trials comparing rituximab-bendamustine induction therapy followed by rituximab maintenance versus the R-CHOP induction treatment plus rituximab maintenance. The sole available comparative study between rituximab-bendamustine and R-CHOP is a phase III randomized trial conducted by StiL (Study Group Indolent Lymphomas, Germany) that is restricted to induction treatment [12] . Conversely, the PRIMA (Primary Rituximab and Maintenance) trial assessed the efficacy of the addition of a maintenance therapy with rituximab in previously treated patients [15] . The efficacy, in terms of the delay of progression observed, in the rituximab maintenance arm of this study was used to adjust the long-term extrapolation of progression-free survival (PFS) in KaplanMeier curves from the StiL study. A phase III randomized trial in relapsed/resistant FL patients was identified and used as the source for the probability of a second relapse [16] .
Transition Probabilities Estimation
To estimate the Kaplan-Meier data from published papers, open source software (Engauge Digitizer) was used. This software allows the conversion of Kaplan-Meier plots into numbers. With the information extracted from KaplanMeier curves, parametric probabilistic functions (lognormal, Weibull, log-logistic) were fitted to extrapolate longterm probabilities. The selection of these functions was based on Akaike information criteria (AIC) and Bayesian information criteria (BIC) goodness-of-fit tests. From the different functions fitted, we selected the functions with the lowest values of AIC and BIC. A log-normal distribution was identified with the best goodness of fit for both PFS and relapse probability (Table 1) . To estimate the functions fitted and parameter values, the survival package from R software was used (Fig. 2) [17, 18] .
Death probabilities considered both the specific risk of death associated with FL and age-dependent general mortality. All-cause mortality rates by age were obtained from the Spanish national registries of the Spanish National Institute for Statistics [19] . The specific risk of death associated with FL was derived from the published data of an epidemiological analysis performed using data from 1978-1999 in a sample of 14,637 US patients [20] . Using a Joinpoint regression model, a coefficient (1.80 % per year) was provided that links the year of FL diagnosis with the annual mortality rate percent change [21] . For modelling purposes, mortality rates were adjusted to the 4-week cycle length.
Utility Values
The utility values used to calculate QALYs from the estimated survival were collected from scientific literature: 0.805 for PF state and 0.618 for progression state; these were obtained through a visual analogue scale by the EuroQol EQ-5D questionnaire in 222 patients with FL from the UK [21, 22] . The utilities were directly applied to the PF and progression health states in the model. No utility decrements were associated with the occurrence of an adverse event.
The Spanish National Health System perspective was chosen. In accordance with the last published recommendations for performing economic evaluations in Spain [23] , a 3 % annual discount rate was applied to both health outcomes and costs. 
Treatments Administered
The simulation began with the administration of the assessed therapies, rituximab-bendamustine or R-CHOP, to patients in the PF state (induction phase) for a maximum of six cycles of the corresponding chemotherapy. After these six cycles, patients without disease progression transitioned to the maintenance sub-state, in which rituximab maintenance (375 mg/m 2 every 60 days) was continuously administered until death, progression or for 2 years at maximum. In accordance with the available evidence [15] , rituximab maintenance was halted at the end of the 2 years for surviving patients without disease progression. These patients remained in the PF state until death or relapse.
The transition to the disease progression state could imply a treatment switch. Chemotherapy patterns for the first and second relapse, after previous initial treatment with rituximab-bendamustine and R-CHOP, were defined by an expert panel to reflect the typical care. The expert panel comprised two haematologists and an oncologist with expertise in the clinical management of patients with FL as well as the authors of this paper. The Delphi method was used to guide the expert panel. A questionnaire was sent to the three experts to request their clinical management strategy for this type of patient. After the experts completed the questionnaires, a meeting was planned to discuss the discrepancies and to achieve a consensus. Only one meeting was necessary to achieve a consensus among experts (additional details available in the electronic supplementary material 1).
As shown in Table 2 , those patients initially treated with the rituximab-bendamustine first-line therapy were assumed to receive rituximab (15 %), R-CHOP (50 %), R-CVP (20 %), R-ESHAP (rituximab plus etoposide, cytarabine, cisplatin and methylprednisolone) (10 %) and rituximabbendamustine retreatment (5 %) during the first relapse, and rituximab (15 %), R-CHOP (5 %), R-CVP (10 %), R-ESHAP (5 %), rituximab-bendamustine retreatment (15 %), bendamustine (10 %), R-FC (rituximab plus fludarabine and cyclophosphamide) (10 %), chlorambucil (10 %) and transplantation (20 %) during the second relapse. The corresponding treatment patterns for patients with the initial R-CHOP first-line treatment were rituximab (15 %), R-CVP (15 %), R-ESHAP (10 %) and rituximab-bendamustine (60 %) during the first relapse and rituximab (15 %), R-CVP (10 %), R-ESHAP (5 %), rituximab-bendamustine retreatment (15 %), bendamustine (10 %), R-FC (15 %), chlorambucil (10 %) and transplantation (20 %) during the second relapse. The doses and duration of each treatment are detailed in Table 2 .
An average cost of chemotherapy in the progression state was calculated for the first and second relapse; these were applied as transitional costs once a patient underwent disease progression (Table 3) .
Treatment and Health State Costs
Total cost estimation included the pharmaceutical and administration costs for chemotherapy in the induction, maintenance and relapse (first and second) states, the prophylactic premedication costs for rituximab-bendamustine and R-CHOP, the management costs for an adverse event following rituximab-bendamustine or R-CHOP therapies and general disease management costs for each health state or sub-state.
Drug costs were calculated based on published ex-factory prices in December 2013 [24] by applying the mandatory deduction established by the Royal Decree Law 8/2010 [25] applicable in December 2013 [26] . The lowest PF progression free, R-CHOP rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone ex-factory prices were chosen for generic drugs. No vial wastage was considered in the cost calculations. Premedication was considered to be prophylactically administered with each cycle of the assessed therapies. All intravenous medications were assumed to be performed at the hospital level in an onco-haematology unit. A unitary cost (€252.41) was computed for each hospital visit for drugs administration.
The disease management costs for each health state and the adverse event management costs were estimated based on the disaggregated resource consumption provided by the multidisciplinary expert panel. The management at PF induction phase was considered slightly different with regard to rituximab-bendamustine compared with R-CHOP therapy.
The first cycle management cost after any relapse (first or second) was assumed to require resources in addition to patient management in the following period; therefore, the management costs for the first and second relapse were both split into costs for the first cycle and the cost for subsequent cycles (Table 3) .
The frequencies of grade 3 or 4 adverse events for rituximab-bendamustine and R-CHOP (alopecia, anaemia, arrhythmia, cardiac failure, erythema, stomatitis, leukocytopenia, lymphocytopenia, neutropenia, febrile neutropenia, peripheral neuropathy, allergic reaction, sepsis and Fig. 2 Kaplan-Meier and parametric curves fitting for PFS and relapses. KM KaplanMeier, PFS progression-free survival, R-CHOP rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone thrombocytopenia) that occurred during the clinical trial [12] were considered and adjusted to the 4-week length of the model's cycle to estimate the risk of each adverse event per the rituximab-bendamustine or the R-CHOP cycle (Table 4) .
From the disaggregate health resource consumption provided by the expert panel as required for the management of each event, the individual cost for the event was estimated and multiplied by the adjusted adverse event frequency. An average management cost for all adverse events was calculated and computed for each rituximabbendamustine or R-CHOP treatment cycle.
Unitary costs for the health resources identified were obtained from a Spanish national health cost database [27] . All costs were expressed in Euros and refer to year 2013 values.
In accordance with the ICUR estimation, the efficiency was established based on the commonly accepted willingness-to-pay threshold in Spain, €30,000 per QALY [28] .
Sensitivity Analysis
Sensitivity analyses were conducted to assess the model's robustness. One-way sensitivity analyses (OWSA) were performed by means of variation of the following parameters: time horizon (15 years and 30 years), patients' average age (63 years in concordance with population median age in clinical trials), discount rate (0 % and 5 %), alternative utility values for relapse in progression disease (±20 %: 0.640 and 0.966 for PF and 0.494 and 0.742 for disease progression) and costs (±20 %). Parametric NA not applicable, R-CHOP rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone, R-CVP rituximab combined with cyclophosphamide, vincristine and prednisone, R-ESHAP rituximab combined with etoposide, methylprednisolone, cytarabine and cisplatin, R-FC rituximab combined with cyclophosphamide and fludarabine distributions with the second best fit to Kaplan-Meier curves (Weibull for rituximab-bendamustine PFS, maintenance and relapses and Exponential for R-CHOP PFS) were applied in an additional scenario to test the uncertainty of the effects of the treatments. Probabilistic sensitivity analyses (PSA) were performed using 10,000 Monte Carlo simulations. Parametric distributions were applied to the input parameters; Cholesky decomposition for parameters on survival functions, gamma for costs, beta for utilities and Dirichlet for relapse treatment patterns (additional details are provided in electronic supplementary material 2).
Results
At the end of the 25-year simulation, first-line treatment with rituximab-bendamustine was more effective than treatment with R-CHOP, yielding 12.86 LYG versus 12.62 LYG. The health benefits measured by the QALYs for treatment with rituximab-bendamustine had a higher benefit (9.63 QALYs) than R-CHOP treatment (9.23 LYG).
In the base case of deterministic analysis, the first-line treatment with rituximab-bendamustine represented a total cost of €68,357 per patient, compared with the total cost for R-CHOP treatment (€69,528). Savings in total costs achieved by the rituximab-bendamustine strategy compared with that of R-CHOP were -€1171. For the PF state, the cost was €6433 higher for rituximab-bendamustine compared with R-CHOP, mainly because of the higher drug costs during the induction phase (treatment, administration and prophylaxis) for the rituximab-bendamustine treatment (€17,671) compared with R-CHOP treatment (€11,850). For the progression disease state, costs that represented rituximab-bendamustine therapy (€27,371) were lower than for R-CHOP therapy (€34,974). According to these results, rituximab-bendamustine treatment was the dominant strategy over R-CHOP treatment. Detailed base case results are presented in Table 5 .
The robustness of the model conclusions was consistent with the OWSA results. Rituximab-bendamustine treatment remained a dominant option over R-CHOP treatment in most of the scenarios tested. In all scenarios in which rituximab-bendamustine treatment was not dominant (15- Progression-first cycle for first relapse €1930
Progression-subsequent cycles for first relapse €1760
Progression-first cycle for second relapse €2206
Progression-subsequent cycles for second relapse €2143
% Represent percentage of patients treated with each therapy in the cohort that initiates with rituximab-bendamustine or with R-CHOP
PF progression free, R-CHOP rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone * Adjusted in the model for a 28-day cycle length year time horizon, 20 % increase on rituximab-bendamustine treatment costs and 20 % decrease on R-CHOP treatment costs, 20 % decrease in second relapse treatment in R-CHOP arm and parametric curves with second best fitting), the ICER and ICUR were below €10,000 per LYG or per QALY, respectively; therefore, rituximab-bendamustine treatment could be considered a cost-effective strategy for any willingness-to-pay threshold above these values. The inputs with the greatest influence on the results were relapse management costs, rituximab-bendamustine treatment costs and utility values. The scenario that tested a 20 % decrease of rituximab-bendamustine treatment cost showed the highest cost saving achieved (-€4453) with rituximab-bendamustine versus R-CHOP therapy (additional details in electronic supplementary material 3).
The PSA results are shown as a cost-effectiveness plane (Fig. 3) and as a cost-effectiveness acceptability curve (Fig. 4) . Rituximab-bendamustine treatment was the dominant strategy over R-CHOP treatment in 53.4 % of the cases. ICUR was below €20,000 per additional QALY in 97.7 % of the cases, and below €30,000 per QALY gained in 99.6 % of the 10,000 simulations performed.
Discussion
The objective of the treatment of FL is to maximize overall survival, maintain the health-related quality of life (HRQoL) and minimize the treatment-related morbidity.
However, FL treatment can often be associated with significant toxicity, with a deleterious impact on health status. Therefore, it is particularly important to consider HRQoL and other patient-reported outcomes in establishing the suitability of a treatment. Cost-utility analysis was considered to be the best method for conducting this evaluation because quality of life is integrated and considered through the utilities values. Nevertheless, the results were calculated either in terms of cost per QALY gained or cost per LYG, which allows us to infer the influence of quality of life on the efficiency ratios.
Economic evaluations are particularly interesting and helpful for decision makers when head-to-head studies comparing the therapies of interest are not available or when uncertainty regarding whether an increase in health benefits is associated with assumable extra costs. Slight differences were observed in the deterministic base case in terms of survival and costs. Final cost savings achieved with rituximab-bendamustine treatment are associated with the lower costs attributed to rituximab-bendamustine treatment in progressed patients (-€7603), which were derived from the delayed transition to the progression state of rituximab-bendamustine-treated patients. For the 25-year horizon, many more patients on the R-CHOP arm experienced first and second relapses, accumulating more associated costs than patients on the rituximab-bendamustine arm.
The potential associated uncertainty in some of the parameters was tested by PSA, which confirmed these results. Rituximab-bendamustine treatment was the dominant option in more than half of the 10,000 simulations. The ICUR was below the willingness-to-pay threshold (€30,000 per QALY [28] ) most frequently used as reference in economic evaluations performed in the Spanish setting in 99.7 % of cases; therefore, it could be concluded that rituximab-bendamustine therapy is a more cost effective first-line treatment strategy than R-CHOP therapy.
The efficiency of first-line therapies for FL has been assessed in other economic evaluations [29] [30] [31] ; however, a comparison between studies is restricted by differences in the methodologies used, monetary year values, perspective, patient management and healthcare system organizations. Two of these economic evaluations explored different treatment sequences that contain R-CHOP but do not include bendamustine [29] or bendamustine as a first-line treatment [30] .
A discrete event simulation instead a Markov model was used in a different study [31] to assess the cost effectiveness of rituximab-bendamustine treatment compared with R-CHOP treatment in the US. The model predicted longer PFS, higher survival and higher costs for rituximab-bendamustine treatment than for R-CHOP treatment, with ICURs resulting in US$29,549 per QALY for indolent lymphoma patients; this is considered to be a cost-effective option.
However, the conclusions from a previous cost-utility analysis in which rituximab-bendamustine therapy was assessed in England and Wales [22] could be worth noting. Incremental cost-effectiveness ratio (€/LYG) rituximabbendamustine vs R-CHOP)
Rituximab-bendamustine dominant
Incremental cost-utility ratio (€/QALY gained) rituximabbendamustine vs R-CHOP
LYG life-year gained, QALY quality-adjusted life-year, R-CHOP rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone
Based on the estimated £5249 per QALY gained ratio (year 2010-2011 values), rituximab-bendamustine first-line therapy was considered a cost-effective strategy compared with R-CHOP therapy for the treatment of indolent NHL, and this benefit was mainly due to the better toxicity profile of rituximab-bendamustine. In particular, for Spain, only a cost-effectiveness analysis of rituximab maintenance in patients who responded to induction therapy at the first line compared with a 'watch and wait' strategy was performed [32] . Rituximab maintenance was considered a cost-effective option for the long term, that is, 30 years (€6253 per QALY), or shorter periods, that is, nearly 6 years (€29,998 per QALY) (year 2011 values). To the best of the authors' knowledge, this study is the first evaluation focused on FL that assessed the lifetime efficiency of a rituximab-bendamustine first-line strategy, considering rituximab maintenance for 2 years as well as up to two potential relapses.
As is inherent to most economic evaluations, certain assumptions have been made. The interpretation of the results should consider the potential limitations. 
Probability of cost-effecƟve
Willingness-to-pay-threshold (€/QALY gained) Fig. 4 Acceptability curve. The black points represent the probability of rituximabbendamustine being a costeffective strategy over R-CHOP assuming the willingness-to-pay thresholds of €0.00, €20,000 and €30,000 per additional QALY. QALY quality-adjusted life-year, R-CHOP rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone
Challenges to this cost-effectiveness analysis include the fact that the life expectancy of patients with FL exceeds the period of available follow-up data and that treatment pathways are more complex than the model structures frequently used for oncology models.
A strength of this model is that the progression state is split into two sub-states to include the complexity of the disease evolution as well as the different management strategies applied over this progression. Although it is clear that FL patients could suffer many relapses during the evolution of their disease, in this model, only two relapses were considered, as much because of the need to simplify the patient transition as the lack of reliable evidence to be used as the input for model feeding. The efficacies of the treatments were obtained from clinical trials conducted on a 63-year-old population and were applied to the hypothetical 58-year-old Spanish cohort. Because better effectiveness rates would be expected in a younger population, this should be considered a conservative approach. The results from the OWSA performed on a 63-year-old cohort revealed the null impact of this input on the results because the influence of this parameter is restricted to mortality rates by age, which have an effect equivalent to both comparators.
Markov modelling is the most common modelling approach used to simulate FL disease evolution. Alternative approaches such as microsimulation or discrete event simulation were considered at the beginning of the modelling process. Finally, we opted for a Markov modelling approach due to the lack of patient-level data with which to feed our model.
HRQoL could be strongly influenced by sociocultural factors. The lack of utility values especially specific to the Spanish population required the use of values referred for a UK population. However, it has been shown that values for EQ-5D health states in Western European countries (Finland, Germany, The Netherlands, Spain, Sweden and the UK) can be described using a common model [33] . Therefore, the UK values assumed in the present model could be extrapolated to the Spanish setting. Nevertheless, the influence of utility values has been tested in the sensitivity analysis and the conclusions did not change. Only one utility value was used for the PF state, regardless of the sub-state (induction or maintenance phase), in accordance with a published opinion that there should be no difference between the sub-states because both groups of patients are in remission/full response [34] . Confronting the lack of alternative utility values, a variation of ±20 % of the base case data was applied. No great influence of utility values on ICER and ICUR was observed, which supports the assumptions applied.
Conclusion
First-line therapy with rituximab-bendamustine was the dominant strategy over R-CHOP therapy in FL patients, showing cost savings and higher health benefits for Spanish NHS patients, despite its higher initial treatment cost.
